ARTICLE | Clinical News

NRX-1074: Phase II data

February 9, 2015 8:00 AM UTC

A double-blind, U.S. Phase II trial in about 140 patients with MDD showed that a single dose of 10 mg IV NRX-1074 reduced mean HDRS-17 scores, the primary endpoint, by 14 points from baseline to 24 ho...